Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that inhibit cytotoxic T lymphocyte antigen 4 (CTLA4) or PD1 and its ligand PDL1 to reactivate the immune system against tumor (254). The gene discussed is CD274; the disease is neoplasm.